Drug intelligence / Profile preview

DIAG723

Development stage: Phase 2
Lead developer: Diagonal Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

DIAG723 is a bispecific antibody designed to cluster key extracellular receptors, specifically targeting ALK1 and BMPR2, to restore ALK1 signaling. This approach aims to promote vascular quiescence and address the underlying causes of Hereditary Hemorrhagic Telangiectasia (HHT) and Pulmonary Arterial Hypertension (PAH). Developed by Diagonal Therapeutics, DIAG723 has shown disease-modifying potential in preclinical studies by preventing and reversing arteriovenous malformations, preventing HHT-associated anemia, and improving survival in animal models.

Other names: PAH (Diagonal Therapeutics)DIAG 723DIAG723DIAG-723

Targets

ACVRL1 (Activin receptor-like kinase 1)BMPR2 (Bone morphogenetic protein receptor type II)

Beyond the preview

Go deeper on DIAG723.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DIAG723.

Explore the full profile